PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1151999
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1151999
Global Kidney Fibrosis Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Kidney Fibrosis refers to excessive production and deposition of extracellular matrix (ECM) proteins in the kidney interstitium. This excessive production and deposition of ECM causes structural damage, impairment of renal function, and leads to end-stage renal disease (ESRD). Diabetes and Hypertension are two leading causes of Kidney Fibrosis. Apart from these two as infectious glomerulonephritis, renal vasculitis, ureteral obstruction, genetic alterations, and autoimmune diseases among others also causes Kidney Fibrosis. The increasing incidence of chronic kidney diseases and rowing awareness towards renal fibrosis treatment as well as strategic initiatives from leading market player are key factors accelerating the market growth.
According to the Centers for Disease Control & Prevention - as of 2021, around 37 million US individual are affected by chronic kidney diseases, witnessing for over 15% of all US adults. Moreover, as per National Kidney Foundation estimates- in the United States more than 1 in 7 adults are diagnosed with chronic kidney disease. In addition, around 90% of individuals with kidney disease are not aware about their disease. Also, rising number of favorable initiatives from government authorities and increasing prevalence of lifestyle diseases would create lucrative growth prospectus for the market over the forecast period. However, complex process associated with regulatory approvals stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Kidney Fibrosis Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America the leading region in terms of market share owing to increasing prevalence of chronic kidney diseases as well as favorable initiatives from government authorities in the region. Whereas Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising healthcare spending as well as growing prevalence of lifestyle diseases such as hypertension and diabetes in the region.
Major market players included in this report are:
Merck & Co.
F. Hoffman-La Roche Ltd.
Pfizer Inc.
Galectin Therapeutics
La Jolla Pharmaceutical Company
InterMune Inc.
ProMetic Life-Sciences Inc.
Genzyme Corporation
BioLine Rx Ltd
Certa Therapeutics
Recent Developments in the Market:
Global Kidney Fibrosis Treatment Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Therapeutics, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Therapeutics
Angiotensin II receptor blockers (ARBs)
Angiotensin Converting Enzyme (ACE) inhibitors
Pirfenidone
Renin Inhibitors
Vasopeptidase Inhibitors
By End User
Hospital
Clinics
Home Treatment
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable